News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Hadasit Ltd. to Assign to Immuron an Oral Immune Modulation Technology Developed at Hadassah Medical Center


4/20/2009 9:13:33 AM

NEW YORK & MELBOURNE, Australia & JERUSALEM--(BUSINESS WIRE)--Hadasit, the technology transfer company of the Hadassah Medical Organization, and Immuron, a biopharmaceutical company, announced today an agreement whereby Immuron will assign from Hadasit a novel oral immune modulation technology that was developed by Hadassah physicians and scientists. This marks Hadasit’s latest successful licensing of early stage intellectual property to a partner.

Read at BioSpace.com

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES